Purple Historical Cash Flow

Stocks . USA . 
Stock . Purple Biotech
PPBT Stock  USD 3.25  0.11  3.27%   
Analysis of Purple Biotech cash flow over time is an excellent tool to project Purple Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Total Cash From Financing Activities of 11.2 M or Change To Inventory of 691.9 K as it is a great indicator of Purple Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
   Cash Flow   Balance Sheet   Income Statement
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Purple Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Purple Biotech is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.

About Purple Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Purple balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Purple's non-liquid assets can be easily converted into cash.
Balance Sheet
Statement
Details
Profit & Loss
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Purple Biotech Cash Flow Chart

At this time, Purple Biotech's Other Cashflows From Investing Activities is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2025, despite the fact that Other Non Cash Items is likely to grow to (1 M).
Stock Based Compensation  End Period Cash Flow  Begin Period Cash Flow  Issuance Of Capital Stock  
Add Fundamental

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most accounts from Purple Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Purple Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.At this time, Purple Biotech's Other Cashflows From Investing Activities is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2025, despite the fact that Other Non Cash Items is likely to grow to (1 M).
 2022 2023 2024 2025 (projected)
Begin Period Cash Flow10.9M15.0M17.3M18.1M
End Period Cash Flow15.0M14.5M16.7M8.4M

Purple Biotech cash flow statement Correlations

Free Cash Flow
Change In Working Capital
Other Non Cash Items
Capital Expenditures
Change To Account Receivables
Net Income
Change To Inventory
Change In Cash
Stock Based Compensation
End Period Cash Flow
Begin Period Cash Flow
Sale Purchase Of Stock
Depreciation
Investments
Net Borrowings
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Free Cash Flow
-0.240.01-0.47-0.210.89-0.580.01-0.82-0.88-0.89-0.46-0.81-0.490.48-0.690.22-0.350.08
Change In Working Capital
-0.24-0.590.320.08-0.030.64-0.10.10.270.30.040.120.750.180.55-0.580.69-0.71
Other Non Cash Items
0.01-0.590.370.38-0.43-0.620.320.270.08-0.14-0.190.17-0.82-0.27-0.430.92-0.880.92
Capital Expenditures
-0.470.320.370.29-0.640.050.440.630.510.18-0.170.59-0.05-0.520.060.26-0.210.34
Change To Account Receivables
-0.210.080.380.29-0.380.160.390.280.350.180.240.45-0.17-0.060.290.51-0.160.29
Net Income
0.89-0.03-0.43-0.64-0.38-0.27-0.13-0.88-0.82-0.74-0.31-0.81-0.10.54-0.43-0.190.06-0.32
Change To Inventory
-0.580.64-0.620.050.16-0.27-0.230.250.480.690.540.410.870.180.89-0.570.82-0.71
Change In Cash
0.01-0.10.320.440.39-0.13-0.230.020.29-0.3-0.170.13-0.41-0.3-0.170.43-0.370.48
Stock Based Compensation
-0.820.10.270.630.28-0.880.250.020.710.640.290.820.2-0.550.360.04-0.020.22
End Period Cash Flow
-0.880.270.080.510.35-0.820.480.290.710.760.440.780.34-0.410.59-0.090.260.01
Begin Period Cash Flow
-0.890.3-0.140.180.18-0.740.69-0.30.640.760.640.660.62-0.220.79-0.350.53-0.3
Sale Purchase Of Stock
-0.460.04-0.19-0.170.24-0.310.54-0.170.290.440.640.370.390.120.66-0.20.42-0.21
Depreciation
-0.810.120.170.590.45-0.810.410.130.820.780.660.370.21-0.610.40.010.150.14
Investments
-0.490.75-0.82-0.05-0.17-0.10.87-0.410.20.340.620.390.210.170.76-0.870.93-0.89
Net Borrowings
0.480.18-0.27-0.52-0.060.540.18-0.3-0.55-0.41-0.220.12-0.610.170.08-0.040.13-0.45
Change To Operating Activities
-0.690.55-0.430.060.29-0.430.89-0.170.360.590.790.660.40.760.08-0.440.72-0.52
Change To Netincome
0.22-0.580.920.260.51-0.19-0.570.430.04-0.09-0.35-0.20.01-0.87-0.04-0.44-0.90.87
Change To Liabilities
-0.350.69-0.88-0.21-0.160.060.82-0.37-0.020.260.530.420.150.930.130.72-0.9-0.91
Issuance Of Capital Stock
0.08-0.710.920.340.29-0.32-0.710.480.220.01-0.3-0.210.14-0.89-0.45-0.520.87-0.91
Click cells to compare fundamentals

Purple Biotech Account Relationship Matchups

High Positive Relationship

Change To Liabilities
+ 0.93
Investments
Change To Netincome
+ 0.92
Other Non Cash Items
Issuance Of Capital Stock
+ 0.92
Other Non Cash Items
Net Income
+ 0.89
Free Cash Flow
Change To Operating Activities
+ 0.89
Change To Inventory
Investments
+ 0.87
Change To Inventory

High Negative Relationship

Issuance Of Capital Stock
- 0.91
Change To Liabilities
Change To Liabilities
- 0.9
Change To Netincome
Issuance Of Capital Stock
- 0.89
Investments
Begin Period Cash Flow
- 0.89
Free Cash Flow
Stock Based Compensation
- 0.88
Net Income
Change To Liabilities
- 0.88
Other Non Cash Items

Purple Biotech cash flow statement Accounts

202020212022202320242025 (projected)
Free Cash Flow(12.2M)(15.2M)(17.0M)(19.2M)(17.3M)(16.4M)
Change In Working Capital(2.4M)550K3.3M274K315.1K201.5K
Other Cashflows From Financing Activities40.7M1.1M(219K)4.1M4.7M5.2M
Other Non Cash Items15.5M(108K)(843K)(931K)(1.1M)(1.0M)
Capital Expenditures156K115K228K3K3.5K3.3K
Total Cash From Operating Activities(12.1M)(15.1M)(16.7M)(19.2M)(17.3M)(16.4M)
Change To Account Receivables501K(316K)313K178K204.7K214.9K
Net Income(28.1M)(17.8M)(21.8M)(19.9M)(17.9M)(18.8M)
Total Cash From Financing Activities68.5M1.5M1.1M5.4M6.3M11.2M
Change In Cash6.9M(357K)4.1M(541K)(622.2K)(591.0K)
Stock Based Compensation2.6M2.1M2.4M1.9M2.2M1.4M
End Period Cash Flow11.2M10.9M15.0M14.5M16.7M8.4M
Begin Period Cash Flow4.4M11.2M10.9M15.0M17.3M18.1M
Depreciation235K231K201K197K226.6K129.2K
Investments(49.6M)13.2M19.9M13.9M16.0M16.8M
Total Cashflows From Investing Activities(449K)(49.6M)13.4M19.9M22.9M24.0M
Change To Operating Activities(225K)(531K)600K2.1M2.5M2.6M
Other Cashflows From Investing Activities69K359K324K772.4K888.3K932.7K
Change To Netincome(249K)18.0M2.4M1.5M1.7M1.6M
Change To Liabilities503K(2.3M)266K799K918.9K964.8K
Issuance Of Capital Stock27.9M564K1.5M1.6M1.4M1.3M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY